Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Lung cancer is the leading cause of cancer deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for 80% of all lung cancers. Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the deadliest cancer-related proteins and plays a pivotal role in the most aggressive and lethal human cancers, including lung adenocarcinoma where it represents one of the most frequently mutated oncogene. Although therapeutic progresses have made an impact over the last decade, median survival for patients with advanced lung cancer remains disappointing, with a 5-year worldwide survival rate of <15%. For more than 20 years it has been recognized that constitutively active signaling downstream of KRAS is a fundamental driver of lung tumorigenesis. However, years of pursuit have failed to yield a drug that can safely curb KRAS activity; up to now no approved therapies exist for KRAS-mutant NSCLC. The aim of this review is to discuss the current knowledge of KRAS-mutated NSCLC, touching upon KRAS clinical relevance as a prognostic and predictive biomarker, with an emphasis on novel therapeutic approaches for the treatment of KRAS-variant NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 11×
“Of note, this study took advantage from the unique nucleophilicity of the mutant cysteine12 thiol, thus adding the benefit of a selective inhibition of mutant KRAS over WT.[82]”
BackgroundInfluentialCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 1×
“Although they confirmed previously data indicating that KRAS is the most frequently mutated gene (22%), followed by NRAS (8%) and HRAS (3%),[13] they did not confirm the overall mutation rate of RAS, which ranged approximately 30% in the COSMIC data set.”
BackgroundA Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 2×
“[7–9] Indeed, RAS mutations are responsible for the abolishment of the GAP-induced GTP hydrolysis of RAS, thereby leading to the maintenance of the GTP-bound active form of the protein [10,11] or for the impairment of the active site conformation and consequently of the intrinsic hydrolysis activity.”
BackgroundDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 1×
“To this regard, novel alternative targeted strategies of enhancing apoptosis (MEK + BCL2/BCL-XL inhibition) or targeting PI3K upstream (MEK + IGF1R inhibition) have already entered the clinical setting.[115] long with the aforementioned potential targets, a number of KRAS-specific synthetic interactions have been rece…”
BackgroundThe Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · cited 3×
“KRAS mutation in non-small cell lung cancer KRAS accounts for 90% of RAS mutations in lung adenocarcinomas and represents the most commonly mutated oncogene in non-small cell lung cancer (NSCLC), affecting nearly 25–30% of western patients.[9] In 97% of cases, KRAS mutations involve exon 2 at codon 12; the rest of the…”
BackgroundEngelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884
Linardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C. A., & Murray, S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70206-7 · Cited by 739 · cited 2×
“In this study, the presence of KRAS mutations was significantly associated with an absence of response to EGFR-targeted therapy in both colorectal cancer and NSCLC.[73] On the other hand, Mao et al.”
BackgroundResultJänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Self-citationDogan, S., Shen, R., Ang, D. C., Johnson, M. L., D'Angelo, S. P., Paik, P. K., Brzostowski, E. B., Riely, G. J., Kris, M. G., Zakowski, M. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3265 · Cited by 639 · cited 2×
“[32] This enhanced susceptibility to tobacco carcinogenesis probably reflects the constitutive variation in genes encoding tobacco carcinogen-metabolizing enzymes, such as the GSTM1 polymorphism of cytochrome P450 phase I detoxifying enzyme CYP1A1, which shows higher expression in the normal lung tissue of female smok…”
BackgroundMaurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116510109 · Cited by 618 · cited 1×
“As a consequence, SOS is unable to activate KRAS protein.[80,81] Ostrem et al.”
BackgroundFrequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
Riely, G. J., Kris, M. G., Rosenbaum, D., Marks, J., Li, A., Chitale, D. A., Nafa, K., Riedel, E. R., Hsu, M., Pao, W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0646 · Cited by 578 · cited 1×
“[31] It should be underlined that despite KRAS mutations having always been supposed to be linked to tobacco exposure they occur in nearly 15% of lung adenocarcinomas from neversmokers patients; therefore, KRAS mutational status cannot be thoroughly predicted on the basis of smoking history alone.[28] Of note, by geno…”
BackgroundIhle, N. T., Byers, L. A., Kim, E. S., Saintigny, P., Lee, J. J., Blumenschein, G. R., Tsao, A., Liu, S., Larsen, J. E., Wang, J., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr523 · Cited by 532
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490 · cited 1×
“As a consequence, SOS is unable to activate KRAS protein.[80,81] Ostrem et al.”
BackgroundA murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446 · cited 1×
“Importantly, the addition of selumetinib provided significant benefit for mice with lung cancer caused by KRAS and TP53 mutations, whereas mice harboring KRAS and LKB1mutations showed primary resistance to this combination therapy.[95] Of note, preclinical data indicate that MEK inhibitors cause inhibition of cell pro…”
BackgroundRequirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429 · cited 17×
“Till date, MEK inhibitors represent the most promising therapeutic approach for patients with advanced KRAS mutant NSCLC. Remarkably, the Ras/Raf/MEK/ERK cascade is frequently upregulated in NSCLC, especially in the presence of KRAS and BRAF point mutations.”
BackgroundInfluentialPuyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415 · cited 17×
“Till date, MEK inhibitors represent the most promising therapeutic approach for patients with advanced KRAS mutant NSCLC. Remarkably, the Ras/Raf/MEK/ERK cascade is frequently upregulated in NSCLC, especially in the presence of KRAS and BRAF point mutations.”
BackgroundInfluentialImplementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
Sequist, L. V., Heist, R. S., Shaw, A. T., Fidias, P., Rosovsky, R., Temel, J. S., Lennes, I. T., Digumarthy, S., Waltman, B. A., Bast, E., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr489 · Cited by 370 · cited 4×
“In a large series of KRAS mutated lung adenocarcinomas, Chiosea et al. showed that patients harboring KRAS mutant MASI had a worse OS.”
ResultInfluentialTranscriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Dry, J. R., Pavey, S., Pratilas, C. A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1577 · Cited by 262 · cited 1×
“[83,84] Preclinical studies demonstrated that selumetinib significantly suppressed tumor growth in KRAS mutant NSCLC xenografts.[85,86] Early-phase clinical studies showed that selumetinib monotherapy exhibits tumor responses, manageable safety and tolerability profile and identified a suitable dose for clinical trial…”
BackgroundKosaka, T., Yatabe, Y., Onozato, R., Kuwano, H., & Mitsudomi, T. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181914111 · Cited by 254
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas
Johnson, M. L., Sima, C. S., Chaft, J., Paik, P. K., Pao, W., Kris, M. G., Ladanyi, M., & Riely, G. J. (2013) · Cancer · doi:10.1002/cncr.27730 · Cited by 166
The interaction of Ras with GTPase‐activating proteins
Wittinghofer, A., Scheffzek, K., & Ahmadian, M. R. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00321-9 · Cited by 135
RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally
Miller, M. S., & Miller, L. D. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2011.00100 · Cited by 76 · cited 1×
“[19,22] However, in vitro and in vivo data suggested a greater oncogenic potential for KRAS mutant G12V (present in approximately 20% of KRAS-mutated NSCLC) compared with other mutations.[23] Worth mentioning is another but unusual KRAS mutation, namely Q22K, which have been detected only in few other cancers such as…”
BackgroundGoldman, J. W., Gandhi, L., Patnaik, A., Rosen, L. S., Hilton, J. F., Papadopoulos, K. P., Tolaney, S. M., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8026 · Cited by 27
Cited by
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Yuan, M., Huang, L.-L., Chen, J.-H., Wu, J., & Xu, Q. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0099-9 · Cited by 679
MEK inhibitors for the treatment of non-small cell lung cancer
Han, J., Liu, Y., Yang, S., Wu, X., Li, H., & Wang, Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01025-7 · Cited by 290
Plangger, A., Rath, B., Stickler, S., Hochmair, M., Lang, C., Weigl, L., Funovics, M., & Hamilton, G. (2022) · Discover Oncology · doi:10.1007/s12672-022-00550-w · Cited by 25
“In wildtype EGFR NSCLCs, a platinum/pemetrexed regimen was inferior for KRAS-mutant versus wildtype KRAS patients and this type of chemoresistance may be due to mutated KRAS-dependent induction of NRF2-mediated cellular stress response [76, 77].”
BackgroundTomasini, P., Mascaux, C., Jao, K., Labbe, C., Kamel-Reid, S., Stockley, T., Hwang, D. M., Leighl, N. B., Liu, G., Bradbury, P. A., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.12.009 · Cited by 22
Zheng, J., Shen, L., Jiang, N., Zhu, Y., Wu, L., Cao, H., Sun, W., Zhou, J., & Zhou, J. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.07.001 · Cited by 6
Metadata
- Authors
- Ricciuti, B., Leonardi, G. C., Metro, G., Grignani, F., Paglialunga, L., Bellezza, G., Baglivo, S., Mencaroni, C., Baldi, A., Zicari, D., & Crinò, L.
- Venue
- Expert Review of Respiratory Medicine
- Publisher
- Informa UK Limited
- Published
- 2015-11-17
- Volume
- 10
- Issue
- 1
- Pages
- 53-68
- ISSN
- 1747-6348 (ISSN-L)
- 1747-6356
- OpenAlex
- W2172948426
- Cited by
- 65
- References
- 25
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.